Reichmann Heinz
Klinik und Poliklinik für Neurologie, Dresden, Germany.
Fortschr Neurol Psychiatr. 2023 Jun;91(6):256-261. doi: 10.1055/a-1785-3632. Epub 2022 May 18.
Patients with Parkinson's disease can apparently benefit from caffeine consumption, as a number of experimental and clinical studies have already shown.
The review examined the available literature on caffeine and Parkinson's disease.
Caffeine can penetrate the blood-brain barrier and exerts its biological effects mainly by antagonizing adenosine receptors. Numerous studies indicate that caffeine and its derivatives theobromine and theophylline are associated with a reduced risk of Parkinson's disease. Caffeine and adenosine antagonists reduce the excitotoxicity caused by glutamate. Evidence from animal models supports the potential of A2A receptor antagonism as an innovative disease-modifying target in Parkinson's disease CONCLUSION: The present review shows that the investigation and synthesis of xanthine derivatives as well as their analysis in clinical studies could be a promising approach in the therapy of neurodegenerative diseases.
正如一些实验和临床研究已经表明的那样,帕金森病患者显然可以从摄入咖啡因中获益。
该综述查阅了关于咖啡因与帕金森病的现有文献。
咖啡因能够穿透血脑屏障,主要通过拮抗腺苷受体发挥其生物学效应。大量研究表明,咖啡因及其衍生物可可碱和茶碱与降低帕金森病风险有关。咖啡因和腺苷拮抗剂可降低谷氨酸引起的兴奋性毒性。动物模型的证据支持A2A受体拮抗作用作为帕金森病一种创新的疾病修饰靶点的潜力。结论:本综述表明,黄嘌呤衍生物的研究与合成以及它们在临床研究中的分析可能是神经退行性疾病治疗中一种有前景的方法。